Human carcinoembryonic antigen (CEA) is the prototypic member of a family of highly related cell surface glycoproteins that includes carcinoembryonic antigenrelated cell adhesion molecule 6 (CEACAM6) and others. CEACAM6 (formerly NCA), which belongs to the immunoglobulin superfamily, is a cell adhesion protein of the CEA family. It is normally expressed on the epithelial surfaces and on the surface of myeloid cells (CD66c). CEACAM6 is a multi-functional glycoprotein that mediates 
described: the immunoglobulin (Ig) superfamily, integrins, selectins and cadherins. 3 The CEACAM are highly glycosylated transmembrane proteins of the Ig superfamily, located on chromosome 19q13.1-13.2, and were described in 1972 ( Figure 1 ). 4, 5 They are involved in modulate cellular processes, such as neovascularization, shaping of tissue architecture, angiogenesis, T-cell proliferation and cell-cell recognition, and regulation of insulin action, and have also been described as bacterial and viral pathogen receptors, such as
Neisseria species, Escherichia coli and Salmonella. 6 Moreover, CEA-CAM play an important role in tumor-associated mechanisms. 7 The CEACAM family consists of membrane-linked glycoproteins anchored to the cell surface either by glycophosphatidyl-inositol (GPI) anchor or a transmembrane domain, as well as secretory glycoproteins. 8 The GPI-anchored members include CEACAM7 (formerly CGM2), CEACAM8 (formerly CGM6), CEACAM5 and CEACAM6
(formerly NCA). 9 CEACAM1 (formerly BGP), CEACAM3 (formerly CGM1), CEACAM4 (formerly CGM7), CEACAM19, CEACAM20 and CEACAM21 are all attached to the cell membrane through transmembrane domains. 2 CEACAMs manifest their function as an intercellular adhesion molecule through GPI anchorage to the cell surface or transmembrane domains. 8 Most of the research has been directed at CEACAM1 due to the homology identified in a number of mammals, making it more accessible as an in vivo model, 10 as well as towards CEACAM5, the gastrointestinal oncofetal antigen first described in 1965. 8 It is found in most carcinomas of the respiratory and genitourinary systems, in breast cancer, and in cancers of the gastrointestinal tract. 11 In contrast, CEACAM6, also referred to as CD66c, is a multi-functional glycoprotein that mediates homotypic binding with other CEA family members and heterotypic binding with integrin receptors. 12 It functions by organizing tissue architecture and regulation of signal transduction, while aberrant expression leads to the development of human malignancies. 12 It was first discovered in proliferating cells of adenomas and hyperplastic polyps in comparison to benign colonic tissue. 13 Overexpression of CEACAM6 modulates cancer progression through aberrant cell differentiation, anti-apoptosis, cell growth and resistance to therapeutic agents. 14 CEACAM6 overexpression in multiple malignancies promotes cell invasion and metastasis, thereby
representing an acquired advantage of tumor cells directly responsible for an invasive phenotype. 15 In vitro studies have shown that antibodies directed against CEACAM6 on overexpressing cells inhibited cell migration, invasion and adhesion. 16 This large gene family can be divided into the CEA subgroup (n = 12, where 5 of them are pseudogenes), the PSGsubgroup (n = l1) and the incomplete non-expressed CGM (CEA gene family member) subgroup (n = 6). 17, 18 These genes were arranged during evolution into 850-kb distal clusters and 250-kb proximal clusters in relation to the centromere, separated by 700 kb of genomic DNA containing a few unrelated genes. 19 CEACAM4, CEACAM7, CEACAM5, CEACAM6 and CEACAM3 are closely clustered in the proximal cluster; CEACAM1, CEACAM8 and PSG/CGM genes are clustered in the distal cluster. 16 Gene amplification is an essential mechanism of insertional mutagenesis, in addition to loss of control mechanisms, structural alterations, chromosome translocations and oncogene activation. The comparative genome hybridization analysis identified DNA copy number changes in all cancers. 20 The region 19q13. Each CEACAM family member has a distinct tissue-specific expression pattern that varies during different stages of development. In healthy human adults, the expression of CEA is mostly found in columnar epithelial cells and mucus-secreting cells of the colon. 
| STRUCTURE OF CARCINOEMBRYONIC ANTIGEN /CARCINOEMBRYONIC AN TIGEN-RELATED CELL ADHE SION MOLECULE 6
The ECM domains of CEACAM6 consist of an Ig variable-like Nterminal domain followed by 6 (AIB l, A2B2, A3B3), 3 (AIB l, A2) or 2 (AlB1) C2-type Ig domains, respectively, as shown in Figure 2 .
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CEACAM6 and CEACAM1 share striking homology at both the nucleotide and amino acid levels. Relative to the CEA family, CEA-CAM1 and CEACAM6 are 80/90% homologous, respectively, at the nucleotide level and 70/85% homologous, respectively, at the amino acid level. 31 While CEACAM6 molecules are bound to the plasma membrane by GPI anchors, CEACAM1 contains a transmembrane domain followed by a cytoplasmic tail. 32 This distinctive structural feature may explain the opposite roles in human cancer of CEA-CAM1 vs CEACAM6.
As mentioned above, CEACAM6 is bound to the plasma membrane through a GPI anchor. Such anchors are synthesized in the endoplasmic reticulum. 33 The eukaryotic GPI anchor consists of a RIZEQ ET AL. Moreover, GPI-anchored proteins are found in specific rafts or micro-domains of the plasma membrane known as detergent insoluble glycolipid domains (DIG). 36 Several members of the Src-family of GTP-binding proteins and protein tyrosine kinases involved in signal transduction pathways are often associated with the cytoplasmic side of DIG. 44 The question of the potential mechanism of CEA/ CEACAM6 effects arises. There are at least 3 key physiological processes that function to maintain the homeostasis of a normal human epithelium: cell proliferation, cell differentiation and apoptosis. 45 The disturbance of these processes, such as through an increase in cell all human adenocarcinomas. Based on these observations, the prevailing hypothesis is that CEACAM6 overexpression plays an oncogenic role. 15 In contrast, transmembrane CEACAM1 was proposed to be a tumor suppressor protein because it is downregulated in many cancers and its forced expression in various cancer cell lines, inc1uding prostate, colon and breast, decreases proliferation and increases apoptosis. 43 However, this generalization becomes blurred based on the following observations: (i) detection of its overexpression in various cancers; 47 (ii) its contribution to tumor aggressiveness; 48 (iii) the nature of its immune suppressive effects; 49 and (iv) its pro-angiogenic properties. 50 The GPI-anchored CEA/CEACAM6 have a variety of tumorigenic effects on cells cultured in vitro and in xenograft mouse models.
Overexpression of CEA and CEACAM6 impedes myogenic, adipogenic, neurogenic and colonic differentiation programs, 41 inhibits anoikis/apoptosis in colon and pancreatic cancer cells, 51, 52 disrupts cell polarization and tissue architecture, 41 increases chemoresistance 53 and enhances liver metastasis. 52 Although earlier studies examined the role of CEACAM6 in gastrointestinal malignancies such as colon and pancreas, numerous other carcinomas (e.g. breast, gastric, thyroid, B-ALL and multiple myeloma) have been shown to overexpress CEACAM6, resulting in increased metastatic potential.
The fundamental role of CEACAM 6 in breast cancer progression will be discussed in detail below.
| Physiological functions of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancer
Carcinoembryonic antigen-related cell adhesion molecule 6 expression may represent an early event in the development of human epithelial malignancies. Breast cancer cells illustrate CEACAM6 better than normal breast tissue. 54 As we have seen in precursor lesions for both colorectal cancer and pancreatic ductal adenocarcinoma (PDA), overexpression of CEACAM6 is predictive of progression to breast cancer. 55 A retrospective analysis of 243 patient samples revealed that CEACAM6 overexpression correlated with tamoxifen resistance. 56 In a multivariate analysis, CEACAM6 overexpression was an independent predictor of disease recurrence. 57 Furthermore, siRNA-mediated gene silencing of CEACAM6 in tamoxifen-resistant MCF7 cell line derivatives reversed anchorage independence and re-established endocrine sensitivity. 57 Previous work revealed that the development of resistance to tamoxifen in breast tumor cells is related to augmented invasive potential 58 as well as CEACAM6 overexpression. 54 The relationship between CEA-CAM6 overexpression and acquired tamoxifen resistance leads to invasion and migration in MCF-7.2A and MCF-7.5C breast cancer cells. 59 CEACAM6 is markedly overexpressed in estrogen-diminished breast cancer cells. These in vitro data were further validated in human breast cancer as CEACAM6 is recurrently overexpressed in the setting of post-adjuvant endocrine therapy (e.g. tamoxifen). In a cohort study of 840 invasive breast cancers and a separate validation cohort of 300 invasive breast cancers, CEACAM6 expression was found to be present in 37.1% (312/840 patients) cases. 26 Interestingly, CEACAM6 expression was highest in HER2+ tumors (67%) and lowest in triple negative breast cancer (25%). 60 The patients in this study were followed for a mean of 56.4 months, and 105 patients developed distant metastatic disease. 26 Expression rates for CEACAM6 were highest for patients with bone metastasis (42%).
The study reported that CEACAM6 adverse prognostic significance for OS was independent of traditional prognostic factors ( Carcinoembryonic antigen-related cell adhesion molecule 6 is overexpressed primarily by colorectal, gastric and pancreatic cancers, with the vast majority of these tumors (>90%) expressing CEA. 62 In addition, it is expressed by the majority of medullary thyroid cancers 63 and more than 70% of non-small cell lung cancers. 64 Reports of expression on many other cancers exist. Overexpression of CEA colorectal cancer was described by inhibition of terminal differentiation, loss of cellular polarization, distortion of tissue architecture, and anoikis resistance, 8 while in lung adenocarcinoma, it induces cell proliferation and anchorage-independent growth. 65, 66 In gastric cancer, CEACAM6 promotes lymph node metastasis, migration and invasion through increasing SRC phosphorylation. 50 In contrast, in B-cell acute lymphoblastic lymphoma, presumed enhancement of anoikis through increased caspase activation as well as upregulation of the AKT cell survival pathway. 50 In addition, in multiple myeloma, CEACAM6 inactivation of CTL (cytotoxic lymphocytes), through binding and cross-linking of CEACAM6 on plasma cells, resulted in T-cell unresponsiveness immune evasion. 51, 67 In addition, in pancreatic ductal adenocarcinoma, increased metastatic potential through increased IGF-I resulted in expression of proteolytic MMP-2 and MMP-9, altering the ECM through SRC-AKT signaling pathway. 68 These findings correlate CEACAM6 overexpression with an increased metastatic phenotype through elevated SRC activity and matrix metalloproteinase 2 (MMP2) expression. Hence, CEACAM6 overexpression through activation of the SRC-AKT signaling provides chemoresistance to gemcitabine in PDA cell lines.
| CONTRIBUTION OF CARCINOEMBRYONIC ANTIGEN/ CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 6 IN CELL SIGNALING
The CEA family plays an active role in multiple signal transduction processes. 69 Using transfected basophile leukemia cells as a model, it has been demonstrated that GPI-bound CEA participates in a stimulatory signal transduction pathway. Caveolin-1 is an integral membrane protein found to co-precipitate with SRC and is required for SRC kinases to activate integrin signaling. 71 The co-clustering of cell surface lipid raft-associated CEA-CAM6 and integrin a 5 b 1 leads to increased fibronectin binding to the cells and recruitment of downstream signaling elements, including ILK, Src family kinases, PBK and Akt/PKB. 72 and, hence, it has been proposed that clustering could activate the integrin signaling pathway. 11 A similar observation was made by another group involving CEACAM6 and integrin a 7 b 3 in pancreatic adenocarcinoma cell lines. 53 Altogether, the GPI-anchored CEACAM can mediate cell signaling through modulation of integrin functions (Figure 4 ). immune-conjugate in a murine xenograft model of PDA. 75 The nonconjugated Mab did not have anti-tumor activity, and showed reversible and modest neutropenia. Further development of an antibodydrug conjugate-based therapeutic approach in PDA has yet to be pursued in early phase clinical trials. 75 
| Immunotoxin-based therapy
Targeting CEACAM6 in PDA using immunotherapeutic strategies has been classified as direct or indirect. 76 Indirectly using the Mab (114) specific for CEACAM6 with no anti-tumor activity mediated crosslinking of CEACAM6, which resulted in cytoplasmic accumulation that increased efficacy of immunotherapy with saporin with caspasemediated apoptosis. history of the tumor and TME and allow novel combination therapies to be developed for treating both solid and hematologic malignancies.
In conclusion, our review highlights the pathologic roles of CEA-CAM6 in the development of multiple human malignancies, warranting an ongoing focus to successfully transition this cell adhesion protein as a primary or adjunctive therapeutic target for anti-cancer therapy in the clinic.
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